OUR SCIENCE

At EVIR Therapeutics, we use gene-modified dendritic cells to activate the immune system against cancer. Our proprietary platform consists of a chimeric receptor, termed EVIR, which endows dendritic cells with the ability to uptake extracellular vesicles released from the patient’s own tumor and to present tumor antigens to the immune system, without knowledge or manipulation of tumor antigens ex vivo.

EVIR-engineered dendritic cells represent a new class of tumor vaccine for personalized therapeutic applications. At EVIR Therapeutics, we are committed to clinically test our innovative vaccination strategy and deploy it to patients with cancer.